The panel accurately and sensitively detects over 1600 variants of clinical significance 05/09/2018 — AUSTIN, Texas — (BUSINESS WIRE) Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy to use […]
The AmplideX DMPK Kit is the first of several new genetics products in 2018 22/05/2018 — AUSTIN, Texas — (BUSINESS WIRE) Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy […]
17/01/2018 — AUSTIN, Texas — (BUSINESS WIRE) Asuragen, Inc., a global molecular diagnostics product company changing the way patients are treated in genetics and oncology by bringing complex molecular tests […]
— Achieves highest speed ever recorded in unbreakable, secure communications — 15/09/2017 — TOKYO — (BUSINESS WIRE) Toshiba Corporation (TOKYO:6502) and Toshiba Research Europe Limited’s Cambridge Research Laboratory in the […]
Amendment of the DNA Identification Act of 1994 is a substantial step forward in making real-time DNA testing of arrestees in the booking environment a reality 21/08/2017 — PLEASANTON, Calif. […]
Revolutionary technology will accelerate utility of gene mapping, biomarker discovery, tumor profiling, and liquid biopsy analysis 03/08/2017 — ANN ARBOR, Mich. — (BUSINESS WIRE) Swift Biosciences, a leading provider of […]
Allows laboratories to generate forensic DNA profiles from extracted and quantified DNA samples in 90 minutes Several crime scene samples tested with the new system uploaded into CODIS, including DNA […]
06/01/2017 — LES ULIS, France — (BUSINESS WIRE) LFB S.A., announced that its Biologic License Application (BLA), requesting marketing approval of Coagulation Factor VIIa (Recombinant) as a treatment for congenital […]
Samsung Bioepis Co., Ltd. today announced that Korea’s Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® – a biosimilar version of Remicade® (infliximab), also known as SB2 – for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis and plaque psoriasis. This marks the second regulatory approval for Samsung Bioepis in Korea. The MFDS approved in September 2015 Samsung Bioepis’ BRENZYS®, a biosimilar version of Enbrel® (etanercept), also known as SB4.
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Benepali® – a biosimilar version of Enbrel® (etanercept), previously known as SB4 – for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) and plaque psoriasis. This marks the first time the CHMP has adopted a positive opinion on an etanercept biosimilar.